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Evidence ofgene deletion ofp21 (WAFl/CIPi), a cycin-dependent protein
kinase inhibitor, in thyroid carcinomas
Y Shi, M Zou, NR Farid and ST Al-Sedairy
Molecular Endocrinology Laboratory, Department ofBiological and Medical Research, King Faisal Specialist Hospital and
Research Centre, Riyadh 11211, Saudi Arabia.
Summary Eukaryotic cell cycle progression is controlled by a host of cyclin/cyclin-dependent kinases (Cdks),
that are themselves regulated by multiple factors, including a group of small cyclin-Cdk inhibitor proteins
(pl5, p16, p21 and p27). The involvement of Cdk inhibitors in carcinogenesis has been demonstrated by the
studies of p16. p53 is frequently mutated in thyroid carcinomas and p21/Wafl is a downstream effector ofp53.
It is conceivable that genetic defects of genes downstream in the p53 pathway could also be oncogenic. We,
therefore, examined a series of 57 thyroid tumour specimens (eight follicular adenomas and 49 carcinomas) for
deletion and point mutation of the p21/Wafl gene. Three different kinds of deletions ranging from 349 to
450 bp were detected in five papillary carcinoma specimens by reverse transcription-polymerase chain reaction
(RT-PCR). All the deletions were involved in the second exon of the p21/Wafl gene. RT-PCR single strand
conformational polymorphism (SSCP) analysis ofremaining samples failed to reveal any point mutations in the
coding region of the gene, except for a polymorphism at codon 31 (Ser to Arg). Genomic Southern blot
analysis did not demonstrate any gene deletion or rearrangement in these samples, indicating abnormal RNA
splicing may be involved. Analysis ofintron-exon boundary and the coding region ofthe second exon did not
reveal any mutation except for a point mutation (C to G) located 16 bp downstream from the splice donor site
ofthe second intron in three out offive samples with p21/Wafl deletions. Whether the mutation plays any role
in aberrant RNA splicing remains to be determined. Among the five samples with p21/Wafl gene deletions,
none of them simultaneously carried a p53 or retinoblastoma (Rb) gene mutation. No p21/Wajl abnormality
was found in the benign adenomas. Thus, 12.5% (5/40) of thyroid papillary carcinoma specimens harboured
p21/Wafl gene deletions. Our data suggest that p21/Wafl gene deletion is involved in thyroid carcinogenesis
and may play an important role in thyroid cell transformation.
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Progression of eukaryotic cells through the cell cycle is
regulated by a family of serine/threonine kinases, the cyclin-
dependent kinases (Cdks), whose catalytic activity is
modulated by association with different cyclins, which
function as regulatory subunits (Norbury and Nurse, 1992;
Hunter and Pines, 1994). Sequential formation, activation
and subsequent inactivation of a series of the cyclin-Cdk
complexes is believed to be essential for orderly transitions
through the cell cycle. A family of small cyclin-Cdk
inhibitor proteins (pl5, p16, p21 and p27) have recently
been identified, which bind and inactivate different kinds of
Cdks, thus participating in the negative regulation of the cell
cycle progression. p15 and p16 inhibit only Cdk4 and Cdk6
among the known Cdks, whereas p21, also known as Wafl
(El-Deiry et al., 1993) and CIP1 (Harper et al., 1993) and p27
can inhibit multiple Cdks, including Cdk2, Cdk4 and Cdk5
(Xiong et al., 1993; Zhang et al., 1993).
The involvement of Cdk inhibitors in carcinogenesis has
been demonstrated by the studies of p16. It has been found
that p16 was frequently deleted or mutated in a wide variety
of human cancer cell lines, as well as in several specific types
of primary tumours (Kamb et al., 1994; Schmidt et al., 1994;
Mori et al., 1994; Jen et al., 1994), indicating that p16
functions as a tumour suppressor. Although p21/Wafl
inhibits growth of human tumour cell lines when introduced
by transfection (El-Deiry et al., 1993), there is only limited
information that the p21/Wafl gene is mutated or deleted in
human tumours (Bhatia et al., 1995).
The p21/Wafl gene is located at 6p21.2 and encodes a
protein of 164 amino acids (El-Deiry et al., 1993). Its
transcription can be activated by the tumour-suppressor p53,
thus providing a critical link between the tumour-suppressing
activity of p53 and the cell cycle control. We have previously
found p53 mutations (Zou et al., 1993a; Farid et al., 1994) in
24% and retinoblastoma (Rb) mutations or deletions (Zou et
al., 1994) in 55% of 49 thyroid carcinoma specimens. The
present study was undertaken to find out whether p21/Wajl
is involved in thyroid carcinogenesis and the extent to which
abnormalities of p21/WaJl correlate with those of p53 and
Rb.
Materials and methods
All tumour specimens were obtained at surgery and were
immediately frozen in liquid nitrogen and stored at -70°C
until processed. The clinical staging of thyroid tumours was
based on the TNM classification introduced in 1987 by the
International Union Against Cancer (Hermanek and Sobin,
1987). Fifty-seven thyroid tumours were studied: eight benign
adenomas, 40 papillary, four follicular and five anaplastic
carcinomas.
Full-length human p21/WaJl cDNA probe was obtained
by reverse transcription-polymerase chain reaction (RT-
PCR) using two flanking primers (see below). The primers
were based on the published p21/Wafl cDNA sequence
(Xiong et al., 1993). The resulting PCR product was verified
by DNA sequencing following subcloning into a TA cloning
vector (Invitrogen Co., San Diego, CA, USA).
RT-PCR and SSCP procedure
Total RNA was extracted by the guanidinium thiocyanate-
phenol-chloroform method as described previously (Zou et
al., 1993b). Total RNA (5,g) was reverse transcribed into
cDNA in a 15 pl volume, using Pharmacia's first-strand
cDNA synthesis kit. The cDNA was then amplified by PCR
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1996in 25 cycles using two primers (5'-ATTCGCCGAGGCACC-
GAGGCA-3', 5'-TTCCAGGACTGCAGGCTTCC-3') flank-
ing the coding sequence of the p21/Wafl gene. Samples were
first denatured at 94°C for 2 min and then submitted to 25
cycles of amplification as follows: 30 s denaturation at 94°C,
30 s annealing at 54°C and 30 s extension at 72°C. For SSCP
procedure, the PCR products were reamplified in a 25 ,ul
volume using two [y-32P]ATP labelled internal primers
together with the flanking primers to generate two over-
lapping fragments, each about 300 bp long, to facilitate SSCP
analysis. The two internal primer sequences are as follows: 5'-
TGCCCAAGCTCTACCTTCCCA-3' and 5'-TCCTCCCAA-
CTCATCCCGGCCT-3'. The SSCP analysis was done as
described previously (Orita et al., 1989a, b). Briefly, 1 ,ul of
each amplified product was diluted in 20 ,l loading buffer
containing 95% formamide, 20 mM EDTA, 0.05% bromo-
phenol blue and 0.05% xylene cyanol, and heated at 95°C for
3 min. An aliquot of 2 ,l was loaded into 5% non-denaturing
polyacrylamide gel with 5-10% glycerol and electrophoresed
at room temperature at 30 W for 4-7 h. The gel was then
exposed to Kodak XAR-5 film overnight at -70°C.
The PCR amplification of the second exon of the p21/
Wafl gene was performed using the following two primers
(Shiohara et al., 1994); 5'-CATAGTGTCTAATCTCC-
GCCGT-3' and 5'-AGCCCTTGGACCATGGATTCTG-3'.
DNA (200 ng) was used for PCR. Samples were first
denatured at 94°C for 2 min and then submitted to 30
cycles of amplification as follows: 40 s denaturation at 940C,
40 s annealing at 55°C and 40 s extension at 72°C.
Sequence analysis
DNA sequencing was performed by the dideoxy chain
termination method after cloning the PCR products into a
TA cloning vector.
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were deleted (nt 45 -432) in three papillary carcinoma
samples, two with stage 3 and one with stage 2 disease. In
mutant C, 349 bp were deleted (nt 93-441) in one stage 2
papillary carcinoma sample. Both mutant B and C deletions
caused a frame-shift and created a stop codon 8 bp and
29 bp downstream from the deletion point, respectively,
resulting in a truncated protein.
The remaining samples were analysed by SSCP for the
presence of point mutations. Significant electrophoretic
mobility shift was detected in six specimens. Sequence
analysis revealed a single nucleotide substitution at codon
31 (AGC to AGA), changing Ser to Arg (Figure 5) in all of
them. This substitution was reported to be a polymorphism
(Chedid et al., 1994; Bhatia et al., 1995).
In order to find out whether p21/Wa/l deletions were also
present in the genomic DNA of those samples, Southern blot
analysis was performed. As shown in Figure 4, no apparent
gene deletion, rearrangement or amplification was present,
indicating that abnormal RNA splicing may be involved in
the deletion of the p21/Wafl gene.
Given that all the deletions are located within the second
exon of the p21/Wall gene (Figure 5), we next amplified by
PCR the second exon from tumour genomic DNA and
examined the intron-exon boundary and the coding region
to see if there are any mutations which may lead to aberrant
RNA splicing. The PCR products were cloned into a TA
vector and a minimum of five clones from each sample were
sequenced. As shown in Figure 5, the entire second exon was
skipped in mutant A and partial second exon was spliced out,
probably by using potential cryptic splice sites: 5'-CA....AG-
3' in mutant B and 5'-AC....TG-3' in mutant C, respectively,
although no mutations were found at splice sites surrounding
the second exon or within the exon. However, one point
mutation (C to G) was found in the second intron 16 bp
from 5' splice site. This mutation was present in samples with
DNA extraction and Southern blot hybridisation
Genomic DNA from tumour samples was extracted as
previously described (Sambrook et al., 1989). Southern blot
analysis was performed by digesting 10 ,ug DNA with EcoRI,
fractionated on 1% agarose gel and blotted onto a nylon
membrane (Hybond-N, Amersham) by capillary transfer. The
DNA on the filter was then sequentially hybridised with
probes for p21/Wafl and human thyrotropin receptor. Probe
labelling and hybridisation were performed as described
previously (Zou et al., 1995).
Results
The coding region of p21/Wajl cDNA was examined for
deletion and/or point mutation by RT-PCR and SSCP in 57
thyroid tumour specimens (eight benign adenomas, 49
carcinomas). The RT-PCR products were analysed on
1.8% agarose gel following ethidium bromide staining.
Smaller than the expected 561 bp fragments were observed
in five papillary carcinoma specimens (Figure 1), ranging
from 100 to 220 bp. Normal-sized fragments were also
present in two of the five samples. Southern blot analysis
of the RT-PCR products could, however, detect normal-
sized fragments as well as the small fragments in all five
samples (data not shown). These small fragments could not
be amplified from eight benign adenomas or peripheral
lymphocytes from ten individuals without known history of
thyroid tumours. They were subsequently subcloned and
sequenced. As shown in Figures 2 and 3, three kinds of
deletions were found, namely mutants A, B and C. In mutant
A, the deletion was from nucleotide (nt) -5 (nt 1 was named
from translation initiation codon ATG) to nt 445, resulting in
a 450 bp deletion in one stage 3 papillary carcinoma sample.
This deletion completely blocks the protein synthesis, as there
is no alternative translation initiation codon ATG in the
remaining sequence. In mutant B, 388 bp coding sequences
1 2 3 4 5
-561 (bp)
-212
-173
- 111
Figure 1 Analysis of RT-PCR products from thyroid tumour
specimens. cDNA fragments were generated by RT-PCR using
the primers covering the coding region of the p21/Wafl gene. The
PCR products were size fractionated on 1.8% agarose gel. The
length of the products is indicated on the right. The DNA marker
is 1 kb ladder from Gibco BRL (lane 1). Lane 2, PCR product
from the wild-type p21/Wafl gene. The smaller sized fragments
(100 -220bp) amplified in thyroid carcinoma samples are shown in
lanes 3, 4 and 5 respectively.p21/Wafn deletions in thyroid cancer
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Figure 2 DNA sequence autoradiographs showing p21/Waft deletion in thyroid carcinomas. Three different deletions were
identified: mutants a, b and c. The deletion point is marked by an arrow. Sequencing reactions were performed using single cDNA
clone as a template.
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Figure 3 Schematic representation of p21/Waft cDNA deletion
in thyroid carcinoma. The wild-type (WT) p21/Wafl cDNA is
shown at the top, and three different kinds of deletion mutants are
shown below. The hatched bar and line represent the coding and
untranslated regions respectively. The dark bars represent the
flanking primers used to amplify the full-length p21Wafj cDNA.
mutant A and C deletions as well as in one of three mutant B
deletion samples. It was not present in three normal samples,
but was found in one thyroid cancer sample without p21/
Wajl deletion. Therefore, the mutation may be a polymorph-
ism and whether it contributes to the aberrant RNA splicing
remains to be determined. It is worth noting that the 5' splice
point of mutant C happens to be in the third nucleotide of
the polymorphic codon 31 (AGC/A), and the third nucleotide
is adenine instead of cytosine (Figure 5). Adenine would thus
serve as a 5' splice donor site of mutant C. However, we do
not know whether this is a chance event or plays any role in
abnormal RNA splicing. Two separate PCRs from original
tumour specimens were performed to rule out the possibility
of enzymatic errors in PCR amplification with Taq
polymerase. The results were identical in the separate
experiments.
Ten per cent (5/49) of thyroid carcinomas (12.5% of
papillary thyroid carcinomas) in this series harboured p21/
a 1 2 3 4 5 6 7
(kb)
-23.1
-9.4
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-4.4
-2.3
-2.0
Figure 4 Southern blot analysis of genomic DNA from thyroid
carcinoma specimens. Genomic DNA (10 g) digested with EcoRI
was fractionated on 1.0% agarose gel and transferred to a nylon
membrane. Hybridisation was carried out with a full-length p21/
Wafl cDNA probe (a). The same blot was rehybridised with a
human thyrotropin receptor cDNA probe to monitor the sample
loading (b). Lanes 1 -5 are tumour specimens with p2l/Waft
mutations. Lanes 6 and 7 are normal control.
WaJl deletions. Among the five p21/Wall deletion samples,
none of them was found to have either a p53 (Zou et al.,
1993) or Rb mutation (Zou et al., 1994). Thus, p21/Waft
appears to be deleted only in those samples without p53 or
cp21/Wafl deletions in thyroid cancer
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p21/Wafl gene
Exon 1 Exon 2
Wild-type
5'-catagtgtctaatctccgccgtgaccagggccttccttgtatctctgctgcagGC GCC ATG
Mutant A
Mutant B
Mutant C
Exon 3
AGAGG TTC TAC
ATG ACAGgtgcggacatgtgcarggaaggactttgtaagggaccaggattctcagaatccatggtccaagggct-3'
CCA TGC GGC AGIC AAG GCC
CGG CGG CAGIACC AGC ATG ACA Ggtgcggacatgtgcacggaagg
CGGAGACAGA \
CGG CAG ACC AGC ATGIACA GgtgcggacatgtgcaXggaaggacttt
Figure 5 Partial nucleotide sequences of three p21 Wafl mutants and intron-exon boundary of p21/WaJl second exon. (a)
nucleotide sequences showing a point mutation in the second intron (gel 1) and polymorphism at codon 31 (gel 3). The mutation
and polymorphism are indicated by an asterisk. The 5' splice site of mutant C is marked by a horizontal line and happens to be in
the third nucleotide of codon 31 (gel 3). Gels 2 and 4 are normal controls used for comparison with gels 1 and 3. (b) schematic
diagram of splicing patterns. The open bars indicate exons which are missing in the cDNA. The upper-case and lower-case letters
represent exon and intron sequences respectively. The splice points are indicated by a vertical line and the primers used to amplify
the second exon are underlined. The premature stop codon resulting from abnormal splicing in mutant B is also underlined.
Mutated or polymorphic nucleotides are shown below their wild-type sequence.
Table I Genetic defects of p53, Rb and p21 in thyroid tumours
Rb gene mutationa p53 gene mutationh p21 gene deletion Both p53 and Rb gene Both p21 and p53 or Rb
Tumour (positiveltested) (positiveltested) (positive/tested) mutation (positive/tested) gene mutation (positiveltested)
Adenoma 0/8 0/8 0/8
Follicular carcinoma 2/4 1/4 0/4 1/4 0/4
Papillary carcinoma 22/40 10/40 5/40 4/40 0/40
Anaplastic carcinoma 3/5 1/5 0/5 1/5 0/5
aZOU et al. (1994). hZou et al. (1993a).
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Rb mutations. The information regarding genetic defects of
p53, Rb and p21 in this series of tumours is summarised in
Table I.
Discussion
We have examined the entire coding region of p21/Wafl
cDNA for deletions and/or point mutations by RT-PCR
and SSCP in 57 thyroid tumour specimens (eight benign
adenomas and 49 carcinomas, including 40 papillary
carcinomas). Subtle p21/Waft deletions have been found in
five papillary carcinoma specimens. The deletions are
involved in the most evolutionarily conserved region (nt
63-180 and nt 390-492) (Huppi et al., 1994), and the
truncated p21/Wafl proteins are probably not functional. El-
Deiry et al. (1993) previously reported that introduction into
human tumour cells of a mutant p21/Wafl with a stop codon
at nt 222 did not result in significant growth suppression,
thus experimentally confirming that the region beyond nt 222
is required for p21/Wafl function. More defined p21 binding
domains involved in the inhibition of Cdk2 and PCNA have
recently been identified (Chen et al., 1995; Goubin and
Ducommun, 1995). The Cdk2 binding domain was located in
the N-terminal part of the protein, between residues 45 and
60 (nt 135- 180). A proliferating cell nuclear antigen (PCNA)
binding region was mapped to the C-terminus of the protein
between residues 142 and 163 (nt 426-489). Cdk2 is required
in the G1-S transition and is found in association with GI
cyclins (Dl, D3 and E) implicated in the control of passage
through the restriction point of cell cycle (Xiong et al., 1992;
Koff et al., 1992; Dulic et al., 1992; Pagano et al., 1993).
PCNA is the auxilliary protein of DNA polymerase delta
(Bravo et al., 1987) and is thought to be involved in DNA
replication and repair processes (Prelich et al., 1987; Shiviji et
al., 1992). p21/Waft interacts with and inhibits both Cdk2
and PCNA, thus controlling cell cycle progression and DNA
replication (Waga et al., 1994). All three kinds of mutants
have lost both Cdk2 and PCNA binding domains. They,
therefore, cannot express their inhibitory activity on either
Cdk2 or PCNA.
Although normal-sized products were present in the five
p21/Wajl mutant samples, the wild-type allele might be
derived from contaminating non-cancerous cells, such as
infiltrating inflammatory cells and stromal cells. Another
possibility is that both wild-type and mutant p21/Wajl alleles
are present in some of the thyroid cancer specimens. This has
been supported by a recent report (Bhatia et al., 1995) that a
heterozygous point mutation at codon 63 (Phe to Leu) of
p21/Wafl was found in a Burkitt's lymphoma cell line. Both
wild-type and mutant p21/Wafl mRNA were expressed in the
tumour cell line. Transfection experiments showed that the
mutant was less efficient in suppressing clonogenicity than the
wild-type. It is, therefore, possible that one wild-type allele of
p21/Wafl may not function sufficiently to cause GI arrest,
thus resulting in uncontrolled cell cycle progression and
tumour formation.
Given that gene deletion and rearrangement are not
found in the tumour genomic DNA, abnormal RNA
splicing is probably the cause of p21/Wafl deletion. The
entire second exon is skipped in mutant A. The common
causes for exon skipping include: (1) mutations in the
conserved sequence at the 5' donor site or 3' acceptor site
(Green, 1986; Zielenski et al., 1995). Most reported cases of
exon skipping are due to a single base substitution that
changes the universal AG dinucleotide at the 3' splice site of
the intron (Green, 1986; (2) mutations in the exon (Dietz et
al., 1993; Matsuo et al., 1991; Wakamatsu et al., 1992). The
exonic mutations would either activate a cryptic splice site
(Matsuo et al., 1991; Wakamatsu et al., 1992), or interfere
with splicing factor binding or RNA secondary structure
(Dietz et al., 1993). Although we could not find any
mutations in the conserved splicing sequences surrounding
the second exon and within the exon, some uncommon
events such as mutations in the second intron or beyond the
region we have examined may participate in the exon
skipping. The potential cryptic 5' splice site (5'-CA....AG-3')
used in mutant B and both splice sites (5'-AG...TG-3') in
mutant C do not follow the 5'GT....AG-3' rule. The GT-
AG rule describes the splicing junctions of eukaryotic
nuclear genes and is highly conserved in most, if not all,
mammalian cells (Padgett et al., 1986). Utilisation of
unconserved cryptic splice sites in mutants B and C may
suggest that a single or multiple splicing factor defect may
be involved in the abnormal splice site selection, and a
partial second exon deletion.
In the present study, we were unable to find any samples
having both p21/Wafl and p53 or Rb mutations. It is known
that radiation induces thyroid tumorigenesis, and recent data
have shown that radiation-induced G1 arrest in thyroid cells
is selectively mediated by the p53-p21/Wafl pathway
(Namba et al., 1995). p-53induced p21/Wafl participates in
the GI/S checkpoint, and inhibits multiple Cdks, including
Cdk4, which stimulates cell division by phosphorylation of
Rb and release ofE2F transcription factor. Loss ofp21/Wajl
would probably affect both p53 and Rb tumour-suppressor
activities. Thus, p21/Wafl mutation alone may be sufficient
to induce thyroid malignancy.
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